Prostate Cancer International announces the development and official opening of its online Active Surveillance Virtual Support Group. This group will meet by webinar or conference call once a month, with the next webinar on Wednesday, December 6, at 2:00 pm Eastern Time (11:00 am Pacific). Registration is required to join.
For more information, click here
Dr. Mark Scholz participated in a tumor board session with a discussion of Prostate Cancer Cases at El Camino Hospital in November 2017.
- Robert Sinha, MD, Medical Director of Radiation Oncology
- Frank Lai, MD, Urological Oncologist/Robotic Surgeon, El Camino Hospital
- Steven Kurtzman, MD, Radiation Oncologist, Director of Prostate Brachytherapy, El Camino Hospital
- Shane Dormady, MD PhD, Medical Director of Oncology, El Camino Hospital
- Mark Scholz, MD, Medical Oncology, Director of Prostate Cancer Specialists, Founder of Prostate Cancer Research Institute
View the recording of the event here
The Prostate Cancer Patient Guide, available from pcf.org is a useful and a must-have resource for prostate cancer patients, loved ones, or caregivers.
Download it from the pcf.org web site here
A Short Course in Prostate Cancer – eBook
The purpose of this short eBook is to provide men facing prostate cancer with a lot of up-to-date information in a compact format.
The information and opinions provided in this book are not specific medical advice for any individual. It should not substitute for medical advice from a healthcare professional. The author is not a medical doctor. The reader is advised that any information or opinions expressed or implied in this book are those of a layman and should not be acted upon without the consent of a licensed physician. This book is not meant to be used, nor should it be used, to diagnose or treat any medical condition. For diagnosis or treatment of any medical problem, consult your own physician.
Download the pdf ebook here.
Risk Assessment systems are not intended to replace individualized clinician-patient decision making, but rather to provide a straightforward instrument for facilitating disease risk classification in clinical decision making and in future research.
The classification developed by D’Amico and colleagues is one of the most widely used and is a good starting point for risk assessment. This system uses PSA level (blood test), Gleason grade (microscopic appearance of the cancer cells), and T stage (size of the tumor on rectal exam and/or ultrasound) to group men as low, intermediate, or high-risk.
Low-risk: PSA less than or equal to 10, Gleason score less than or equal to 6, and clinical stage T1-2a
Intermediate risk: PSA between 10 and 20, Gleason score 7, or clinical stage T2b
High-risk: PSA more than 20, Gleason score equal or larger than 8, or clinical stage T2c-3a
Limitations: Does not account for multiple risk factors
Read more and access the risk assessment calculator here on the UCSF site
According to an article in the journal Cancer, men with low-risk prostate cancer diagnosed and managed at high-volume hospitals are 3.6 times more likely to be managed on active surveillance than those managed at low-volume institutions.
Read more here on Prostate Cancer InfoLink
There are few physicians around the world who have as much experience in managing men on active surveillance as Dr. Klotz and his colleagues at the Sunnybrook Center near Toronto, Canada. They have built their experience carefully over time. They have carefully integrated and studied the value of techniques like multi-parametric MRI scans, MRI-guided and MRI/TRUS fusion-guided biopsies, molecular testing, etc. into the management protocols that they use.
Klotz and his colleagues continue to believe that active surveillance can still be a reasonable option for many patients with “favorable” forms of intermediate-risk prostate cancer, especially if they have other co-morbid conditions that could lead to their deaths within the next 10 to 15 years.
Watch video on www.urotoday.com
Following a prostate cancer diagnosis, patients are faced with a multitude of care options, the advisability of which is influenced by patient factors and by cancer severity or aggressiveness. The ability to categorize patients based on cancer aggressiveness is invaluable for facilitating care decisions.
Accordingly, these guidelines for the management of localized prostate cancer are structured first, to provide a clinical framework stratified by cancer severity (or risk group) to facilitate care decisions and second, to guide the specifics of implementing the selected management options.
In Scope: active surveillance, observation/watchful waiting, prostatectomy, radiotherapy, cryosurgery, high intensity focused ultrasound (HIFU) and focal therapy.
Out of Scope: Secondary or salvage treatment for localized prostate cancer that persists or recurs after primary definitive intervention, and primary treatment of locally advanced/metastatic disease.
Read more on www.auanet.org
Genomic testing is done on cancerous tissue taken from the prostate in order to provide information about how your prostate cancer might behave. By looking at the genetic makeup of the cancer, these tests may help predict whether your prostate cancer grows slowly or aggressively.
Genomic testing can be performed on both biopsy tissue and on tissue from an entire prostate following a prostatectomy.
Read more on Zero